Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

New cardiovascular device categories proposed for the 2023/24 High Cost Device List in England

24 Jan 2023

In December 2022, NHS England published a preliminary 2023/25 NHS Payment Scheme, which will replace the National Tariff Payment System from April 2023, and launched a consultation. The deadline for comments submission is January 27, 2023.

As in the previous year, all High Cost Device List categories will be excluded from the basic payment mechanism. Two new cardiovascular categories are proposed for inclusion in the 2023/24 High Cost Device List (Annex A NHS Payment Scheme prices workbook; Annex A will be updated and reissued for 2024/25):

  • Antibacterial envelope for the cardiac implantable electronic device;
  • Mitral valve repair and replacement devices: includes Mitraclip, Pascal, and Tendyne devices.

Both new categories are commissioned by NHS England, reimbursed centrally through the SSDP (Specialised Services Devices Programme), and should be ordered via the NHS Supply Chain Central Procurement Visible Cost Model (VCM) where available.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.